cyrilzakka/clinical-trials huggingface dataset:
Brain Enhancement Training Towards Elders Resilience to Aging, Phase IIB

This study aims to examine the longer-term benefits of a novel, neuroplasticity-based, computerized and web-deliverable training program (PACR-CT) five years from the initial 10 weeks of training from our Phase II study - Protocol #: PSC-0605-17 (Aim 1) and test the interactive effect of previous training and 10 weeks of booster training (Aim 2). Both the study and the software being investigated meet the criteria of Non-Significant Risk.

This study will employ a single arm, open label design with use of the PACR-CT with all participants who completed the Phase II study, as well as approximately 60 new participants (with a goal of 40 completers) who are age-matched and untrained older adults. After consent, only the new, untrained participants will complete the screening visit. Then all participants will perform the pre-training visit (cognitive and functional assessments, MRI/fMRI and blood draw), followed by 10 weeks of training, and then followed by post-training visit (cognitive and functional assessments and MRI/fMRI).

Eligibility Criteria:
Inclusion Criteria:

* Participant must be 70 years of age or older
* Participant must be a fluent English speaker
* Participant must have adequate sensorimotor capacity to perform the program, including visual capacity adequate to read from a computer screen at a normal viewing distance, auditory capacity adequate to understand normal speech, and motor capacity adequate to control a computer mouse
* Participant must not have evidence of dementia as indicated by the Montreal Cognitive Assessment (MoCA)

Exclusion Criteria:

* Participant with any medical illnesses, injuries or conditions predisposing to imminent functional and/or cognitive decline
* Participant requiring caregiver assistance in dressing/personal hygiene
* Participant with severe visual deficits (including visual neglect, partial field cuts, anopias) and/or severe hearing deficit that would prevent use of the computerized treatment program
* Participant with recent participation of computer-delivered cognitive training within 2 years of consent
* Participant with claustrophobia or any other contraindication to MRI scanning
* Participant with inability to complete a 1-hour MRI
* Pregnant women
* Participant with any implanted devices above the waist (e.g., cardiac pacemaker or auto-defibrillators, neural pacemaker, aneurysm clips, cochlear implant, metallic bodies in the eye or central nervous system, any form of wires or metal devices that may concentrate radio frequency fields)
* Participants with active suicidal ideation with specific plan and intent or suicide-related behaviors within 2 months of consent as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Randomized Controlled Trial of Multi-Source Feedback to Pediatric Residents

The purpose of this study is to test whether multi-source feedback, including self-assessment and tailored coaching, improves resident communication skills and professionalism. We hypothesize that residents who are assigned to receive multi-source feedback, in addition to receiving standard feedback, will improve significantly more than residents receiving standard feedback alone, as measured by parent and nurse ratings of specific behaviors over time.


Eligibility Criteria:
Inclusion Criteria:

* Residents entering their first year of training
* Scheduled for the two pediatric inpatient rotations where parent and nurse evaluations would be collected

Exclusion Criteria:

* Residents from combined Internal Medicine/Pediatric training programs
Rheopheresis as Adjuvant Treatment of Calciphylaxis

We propose to set up a prospective randomized controlled trial to control the security and assess the efficacy of adjuvant treatment by rheopheresis in necrotizing-ulcered calciphylaxis in the hemodialysis population.

Calciphylaxis, also known as uremic calcifying arteriolopathy (UCA), is a rare disease that causes painful ischemic skin lesions due to microvascular calcification and thrombosis of the dermis and subcutaneous adipose tissue. Patients with end-stage renal disease (ESRD) are the main target for calciphylaxis. Rheopheresis is a therapeutic apheresis to treat microcirculatory disorders. This double filtration plasmapheresis eliminates a defined spectrum of high molecular weight proteins from human plasma including relevant factors for vascular inflammation and thrombose. We propose a prospective randomized controlled trial to compared the efficacy of rheopheresis as adjuvant treatment to the standard of care compared to standard care with Sham-apheresis.

Eligibility Criteria:
Inclusion Criteria:

* Calciphylaxis with at least one ulcerated or necrotizing lesion
* End stage renal disease requiring hemodialysis
* Weight superior to 30kg
* Subject affiliated to or beneficiary of a social security system
* Subject having signed written informed consent

A patient with progressing calciphylaxis to ulcerate or necrosis despite conventional treatment may also be included.

Exclusion Criteria:

* KARNOFSKY Performance Status Scale inferior to 30%
* Life expectancy (independently of calciphylaxis) estimated \< 6 months according to a referring physician expert in hemodialysis
* Uncontrolled infection (persistence of fever despite appropriate antibiotic therapy)
* Common variable immunodeficiency
* Albumin allergy
* Contra-indication to stop anti-vitamin K treatment
* Severe cognitive or psychiatric disorders, patients unable to give an informed consent or unwilling to participate in the study
* Pregnancy or breastfeeding and all the other categories of people with special protection according to the French Code de la Santé Publique (CSP): patients under legal supervision, patients hospitalized without contentment, patients admitted in social or sanitary structures for care and not research, and patients in emergency situations.
Detection of Aspergillus Fumigatus and Sensitization in COPD Patients With Bronchiectasis vs Without Bronchiectasis

A single center case-control study with 100 COPD patients will be organized to compare patients with and without bronchiectasis with regard to the presence of Aspergillus in sputum samples, Aspergillus sensitization and vitamin D. Induced sputum samples will be optimized for culture, Aspergillus galatomannan analysis and RT-PCR.

This study is part of a larger project in which we assume that chronic respiratory infection by Aspergillus fumigatus and the accompanying immune response play an important role in the development of bronchiectasis in COPD. We suspect that this mechanism is controlled by vitamin D and it fails by suppression of the vitamin D receptor by Aspergillus fumigatus.

The present study is designed by the Laboratory of pneumology and will be conducted in collaboration with the Laboratory of clinical bacteriology and mycology of the Catholic University of Leuven.


Eligibility Criteria:
Inclusion Criteria:

* Established diagnosis of COPD by medical doctor (based on clinical history or pulmonary function test)
* Smoking history of at least 10 pack-years
* CT Thorax available for assessment of bronchiectasis
* FEV1 \>= 30%

Exclusion Criteria:

* Mechanical or non-invasive ventilation
* Other main respiratory diagnosis other than COPD
* Active mycobacterial disease
* Immunosuppression other than steroids
* Active cancer treatment
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial

This research puts liver biopsy as the enrollment screening criteria and the primary efficacy assessment indicators. Patients at different developmental stages of hepatitis B related liver fibrosis are respectively diagnosed and treated by Traditional Chinese medicine to determine optional diagnosis and treatment plan of traditional Chinese medicine to screen the advantage-treated population and to establish a treatment program, which can save national medical resources, for clinical application of Traditional Chinese medicine Diagnosis and Treatment blocking and reversing hepatitis B-related liver fibrosis. The research can help to build automation pathological analysis and diagnosis systems and non-invasive clinical assessment criteria and models of liver fibrosis which can be applied in clinical. It can also help to realize electronic patient data collection and management, to establish patients management centre and follow-up database. Then it will help to improve clinical efficacy of being blocked and reversed chronic hepatitis B related liver fibrosis by Chinese medicine Diagnosis and Treatment program, to reduce the incidence of liver cirrhosis and hepatitis B-related mortality, to prolong patients' survival and improve patients' quality of life, to make clinical efficacy, which is about Traditional Chinese Medicine blocking and revering chronic hepatitis B-related liver fibrosis, increase by 15% or more .


Eligibility Criteria:
Inclusion Criteria:

Inclusion criteria of chronic hepatitis B related liver fibrosis:

1. Age from 18 to 65 years old, male or female;
2. Consistent with the diagnosis criteria of chronic hepatitis B;
3. liver fibrosis(liver biopsy) stage F ≥ 3 (Ishak), HBV DNA ≥ 104 copies / ml (or ≥ 2000 IU / ml) were;
4. TCM syndrome type: blood stasis, blood deficiency with toxic heat retention;
5. Not taking over nucleoside antiviral in one year, no drug treatment of liver fibrosis in six months;
6. Signed informed consent.

Exclusion Criteria:

1. liver fibrosis(Liver biopsy) stage F \<3 (Ishak);
2. Combined with other severe chronic hepatitis, cirrhosis, liver cancer and other severe or end-stage liver disease;
3. Accompanied by uncontrollable heart, kidney, lung, endocrine, blood, metabolic and gastrointestinal serious primary disease; or mental illness;
4. Pregnant or lactating women;
5. Patients with allergic constitution or allergic to TCM used;
6. Not be prescribed medication, poor compliance, incomplete data affecting the efficacy and safety of those judgments;
7. Patients unsuitable for this trial in Researchers' consideration;
8. Co-infection with other viral liver disease.
MR in Patients With Collagen VI Related Myopathies

Collagen VI-related diseases include Bethlem myopathy and Ulrich dystrophy. They are both caused by decreased levels or a lack of collagen VI. The first symptoms can be present at birth as joint laxity and hypotonic muscles; often seen with luxation of the hip and scoliosis. During childhood, patients may develop contractures of fingers, wrists, elbows and ankles. Muscle weakness often appears in childhood to early adulthood and is progressive. It often results in walking difficulties.

There is no treatment available for Behtlem and Ulrich dystrophies.

The primary aim of this study is to investigate the pattern of involved muscles, the function and quality of the muscles and the disease severity using MRI.

See above

Eligibility Criteria:
Inclusion Criteria:

* confirmed Bethlem myopathy or Ulrich disease

Exclusion Criteria:

* All contraindications for undergoing an MRI scan
The Effect of Acupressure in Improving Constipation Among Inpatients in Neurology Departments

As a form of non-invasive auxiliary care, Traditional Chinese Medicine acupressure can prevent constipation, reduce medication for constipation, save medical costs, and alleviate constipation among inpatients in neurology departments, as well as improve patients' general ease and comfort of defecation, thereby improving their quality of life. It also provides clinical nursing staff with a more effective, safer, and more comfortable auxiliary method of preventing constipation, and can be used as a reference for the nursing of such patients.

Background: Constipation is a common problem among geriatric patients and in neurology departments. However, using stool softeners and enemas yield only temporary effects and may even lead to alternating constipation, diarrhea, and metabolic disorders. Because of its non-invasive nature, Acupressure can be used as adjuvant therapy of integrated traditional Chinese and western medicine to prevent constipation among inpatients in neurology departments. It is necessary to verify that Acupressure can be applied to avoid and alleviate patients' constipation, improve their comfort, and improve their quality of life.

Objective: To explore the effect of Acupressure in alleviating constipation among inpatients in neurology departments.Method: A randomized controlled two-group pre-test and post-test experiment design were adopted in this study; neurology department inpatients were randomly assigned to either the experimental group, which comprised 64 subjects receiving Acupressure on three acupoints (Tianshu, ST25: Stomach Meridian 25; Zhongwan CV12: Conception Vessel 12; Qihai CV6: Meridian Vessel 6) or the control group which comprised 64 subjects receiving routine nursing and fake Acupressure. The research tools included the Bristol Stool Form and Constipation Assessment Scale.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 20 years old
2. Established diagnosis of stroke (ischemic, hemorrhagic acute phase)
3. NIHSS 1-20 points
4. Undiagnosed within three months before admission With intestinal disease and no rectal resection
5. meeting the diagnostic criteria for functional constipation (Rome IV).

Exclusion Criteria:

1. Abdominal surgery or abdominal radiotherapy within three months
2. Abdominal cancer including liver, large intestine, lymph, and pelvic cavity, etc.,
3. Massive ascites
4. There are implants in the abdominal cavity, such as V-P Shunt, L-P Shunt, CAPD, etc.
Social and Prognostic Inequalities in Patients Hospitalised for Cerebrovascular Accident (CVA) in Four Contrasting French Departments

This study should also raise questions about the interest and feasibility of establishing a permanent registry of CVA in the Antilles and Guyana. Indeed in coming decades, the expected doubling of the population of persons aged over 60 years and the foreseeable changes in lifestyle will increase the burden of this disease, in particular since the region is marked by a high prevalence of arterial hypertension and diabetes and a high level of precarity. In addition, this study will provide epidemiological information on CVA, its risk factors and management, which are non-existent for the department of French Guyana where the health environment is manifestly insufficient. These data should make it possible to better evaluate the resources available and the healthcare needs in Guyana.


Eligibility Criteria:
Inclusion Criteria:

* Pre- inclusion
* Patients who have received information about the study (directly or via a person of trust),
* Patients aged more than 18 years,
* Patient hospitalised for a suspected first symptomatic CVA (whatever the mechanism), preceded or not by a transient ischemic attack (TIA),
* Patients with a cerebral imaging examination (CT-scan and/or MRI),
* in Guyana, suspicion of a first CVA according to WHO clinical criteria and who died before the authorised images for descriptive purposes,
* Patients able to answer questions personally or through a parent or a person of trust.

Definitive inclusion

- Patients with confirmed CVA diagnosed according to clinical criteria (WHO criteria) and imaging criteria.

Exclusion Criteria:

* - Patients who refuse to take part in the study,
* Patients with prior symptomatic CVA,
* Patients without cerebral imaging (except in Guyana, for patients with suspected CVA who died before imaging),
* Patients with another severe evolutive disease that could cause death in the weeks following the CVA,
* Patients who cannot be contacted by telephone at 1 month.
PuraPly™ Antimicrobial Wound Matrix and Wound Management

The PuraPly Antimicrobial Wound Matrix (PuraPly AM) case series is a prospective, observational study for patients who have received PuraPly AM which consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) and is intended for the management of wounds; no experimental intervention is involved.

The purpose of the case series is to assess the ability of PuraPly AM to meet wound specific treatment goals including management of bioburden, support of granulation tissue formation and support of wound closure. Patients will undergo clinical assessments and receive the standard of care as determined by the treating physician.

The case series is being undertaken to better understand PuraPly AM utilization and subsequent healing outcomes as well as to evaluate the effects of concomitant wound therapy on healing. Patient's participation may involve follow-up for up to 12 weeks following application of PuraPly AM.

Eligibility Criteria:
Inclusion Criteria:

1. Participant is at least 18 years of age
2. Participant has read, understood and signed and Institutional Review Board (IRB) approved Informed Consent Form (ICF).
3. Participant has at least 1 wound appropriate for receiving PuraPly AM, including

   * Partial and full-thickness wounds
   * Pressure ulcers
   * Venous ulcers
   * Diabetic ulcers
   * Chronic vascular ulcers
   * Tunneled/undermined wounds
   * Surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence) h. Trauma wounds (abrasions, lacerations, second-degree burns, skin tears) i. Draining wounds

Exclusion Criteria:

1. Participant has a known sensitivity to porcine materials
2. Participant has a third-degree burn
3. Participant has a known sensitivity to polyhexamethylenbiguanide hydrochloride (PHMB)
4. Participants receiving concurrent treatment with other topical antimicrobials or skin substitute products
Longitudinal Tracking and Intervention Platform for Medicare Advantage Patients

This study investigates whether a health tracking platform improves an elderly person's health with regards to frailty over the course of a year. Secondary research questions examine which instruments are the best predictors of frailty to improve preventative measures in the future.

All patients presenting to the Annual Wellness Visit at Stanford Hospital will be considered for this study. Eligible who consent will be asked to conduct several activities, which will be video taped and timed.

The activities include:

* Timed up and go: patients will be asked to rise from a chair and walk 10 feet (3 m), turn, walk back to the chair, and sit down.
* QuickDASH tasks: open a jar, carry a shopping bag, cut food with a knife, wash back, wash a wall, and hammer a piece of wood.
* KOOS JR tasks: go up/down stairs, stand upright
* PROMIS PF tasks: lift heavy object repeat x5, shoelace or buttons, wash hair

Patients will then be asked to complete a survey consisting of a number of validated questionnaires used to collect patient reported outcome measures and assess frailty. Patients will be randomly assigned to one of two conditions, the control condition or the frailty wellness platform condition. Patients assigned to the frailty wellness platform condition will be given an orientation to a health tracking program. They will be asked to fill out the questionnaires at 3 separate time points on the program site (accessed via phone or computer) at 3 months, 6 months, and 9 months, following orientation. One year later, at the patient's second Annual Wellness Visit, the patient will be asked to fill out the Health Risk Assessment and the study will conclude.

Eligibility Criteria:
Inclusion Criteria:

* geriatric patients \>65 years of age

Exclusion Criteria:

* none
Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell

Prevalence of diabetes is increasing rapidly both in China and all over the world.Hyperglycemia is an important risk factor and major hazard to cardiovascular and cerebrovascular diseases and even dangerous to human health."High glucose toxicity "cause pancreatic β cell non-physiologic and irreversible damage.It is an important cause of β cell dysfunction.High glucose toxicity further suppresses insulin secretion of β cell, further even β-cell function failure.It is urgent to explore more effective and safety treatments which can also protect islet cells function.How to release high glucose toxicity , reverse the toxic effects of hyperglycemia on islet β cells as early as possible, and to maximize recover and protect the pancreatic β cell function is the keypoints of this study.Our aim is to explore the non-inferiority of new antidiabetic drugs DPP4 inhibitors on releasing glucose toxicity and protecting islet β cell function compared with traditional treatments on newly diagnosed type 2 diabetes,compare efficacy and safety of different oral antidiabetic drugs and insulin on newly diagnosed type 2 diabetes patients with high glucose toxicity and compare differences of different oral antidiabetic drugs and insulin on protecting pancreatic β-cell function.

Patients were divided into 3 groups:

1. DPP-4 inhibitor treatment group (45 cases): DPP-4 inhibitor (sitagliptin phosphate) combined with metformin and/or acarbose;
2. insulin treatment group (45 cases): insulin (insulin glargine or insulin detemir) and/or metformin;
3. Sulfonylureas treatment group (45 cases): sulfonylureas combined with metformin and/or acarbose;

Eligibility Criteria:
Inclusion Criteria:

* newly onset
* type 2 diabetes
* BMI 18-30kg/m2
* FBS≧11.1mmol/L，GHbA1c≧9%
* urine ket ≦(1+)
* Normal liver and kidney function

Exclusion Criteria:

* type 1 diabetes
* renal or hepatic insufficiency
* Severe ketoacidosis
* Treatment with corticosteroids, immunosuppressive agents or cytotoxic drugs
* Severe systemic disease
* History of pancreatitis or pancreatic surgery
* Pregnant and lactating women
Regulation of Intracerebral Pressure During Electroconvulsive Therapy

The purpose of this study is to determine whether electroconvulsive therapy (ECT) has an influence on pressure within the human brain before, during and after ECT.

1. Aim:

   1. Our main objective concerning this study is to determine to what extent ECT does lead to an increase of the Pulsatility Index (as an indicator of intracerebral pressure) measured by a Transcranial Doppler Device (TCD).
   2. As a secondary objective we want to compare the PI measurements with simultaneously measured systemic blood pressure.
2. Study design:

   a.Observational study: cohort study
3. Treatment:

   a. Treatment as usual, PI and blood pressure measurement at baseline, just before ECT, during and 5 minutes after ECT. Data will be collected during unilateral treatment during 3 consecutive ECT treatments.
4. Endpoints:

   1. A minimum of sixteen patients are needed according to the power analysis.

Eligibility Criteria:
Inclusion Criteria:

* Temporal window to measure PI
* Major depression
* Psychotic depression

Exclusion Criteria:

* Under 18 years of age
Comparison of Capsular Stretching and Passive Joint Mobilization in Idiopathic Adhesive Capsulitis

The aim of this research is to determine the effects of capsular stretching versus passive joint mobilization on Pain, range of motion and Quality of life in patients with Idiopathic Adhesive capsulitis.

In reference study, patients with Adhesive capsulitis were given the option to examine the immediate effects of posterior capsule stretching and scapular mobilization. They came to the conclusion that extending the posterior capsule improved shoulder range of motion. Current study will assess all shoulder movements and also showing effect on Quality of life of patients with adhesive capsulitis.

Eligibility Criteria:
Inclusion Criteria:

Both genders

* Age : 30-50 years
* Pain and Restricted movements of shoulder.
* Patient With Adhesive Capsulitis of Stage 2

Exclusion Criteria:

* Patient with any Intrinsic Etiology such as Haemarthrosis, rheumatoid arthritis ,infection or gout
* Patient with any severe trauma, Shoulder dislocation, subluxation or ligament injury of the shoulder
* Fractures of the shoulder
* Peripheral neurological involvement in the upper extremity.